H.R. 10272, known as the 'End Gas Station Heroin Act,' aims to combat the rise of potent synthetic opioids sold in commercial settings, often referred to as 'gas station heroin.' The bill proposes several key actions:
1. **Schedule I Classification**: It seeks to classify two synthetic opioids, MGM-15 and MGM-16, as Schedule I controlled substances, indicating they have a high potential for abuse and no accepted medical use.
2. **Threshold-Based Scheduling**: The bill intends to place synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl into Schedule I when their concentrations exceed specific thresholds, targeting enhanced or concentrated forms of these substances.
3. **Enforcement Expansion**: It broadens enforcement capabilities against manufacturers and distributors of emerging synthetic opioids, allowing authorities to treat any such opioid as Schedule I if it is more potent than morphine and is being commercially distributed, even without formal scheduling.
4. **Exemptions**: Natural kratom products are exempted, provided they do not exceed specified concentration limits of the aforementioned compounds and are not produced through manufacturing processes.
5. **User Protections**: The bill explicitly prohibits criminal or civil enforcement against individuals for simple possession or personal use of these substances, focusing enforcement efforts on manufacturers and distributors.
These measures are designed to address the public health risks associated with the proliferation of synthetic opioids in consumer markets.
Supporters of H.R. 10272 commend the bill for proactively addressing the public health crisis posed by synthetic opioids. The Department of Justice has emphasized the necessity of such measures to prevent these potent substances from becoming a broader threat, highlighting the bill's role in protecting communities from drug addiction and abuse. The DEA's temporary scheduling of related compounds underscores the urgency and importance of legislative action in this area.
Critics of H.R. 10272 express concerns that the bill may inadvertently impact the kratom industry and its consumers. While the bill exempts natural kratom products within certain concentration limits, there is apprehension that the legislation could lead to increased scrutiny and potential restrictions on kratom, which some individuals use for therapeutic purposes. Additionally, there are worries that the broad enforcement provisions might result in unintended consequences for small businesses and consumers who rely on these substances.
The analysis of H.R. 10272, which seeks to schedule MGM-15, MGM-16, synthetic 7-hydroxymitragynine, and Mitragynine Pseudoindoxyl as Schedule I Controlled substances, reveals no direct industry overlaps with the sponsor Lance Gooden's top donor industries. Gooden's largest donor sector is Health Professionals, contributing $120 million, which does not have a clear connection to the substances being scheduled in this bill. The second largest donor sector is Retired individuals, contributing $37.5 million, which also lacks relevance to the bill's subject matter. Therefore, the potential for conflicts of interest appears minimal, as the financial support from these industries does not suggest an influence over the legislation concerning controlled substances.
Top industries funding Lance Gooden, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
